Anthropic and Nvidia Bet on Biotech: $140 Million for Basecamp Research

The life sciences industry is receiving a significant new financial boost from major players in artificial intelligence. Basecamp Research, a UK-based startup specializing in using AI to accelerate drug development, has raised $140 million in a Series C funding round, according to Tech.eu.

What makes this deal particularly notable is the makeup of its investors. Nvidia, already a familiar name in the AI startup funding ecosystem thanks to its computing resources essential for training models, continues to expand its strategic portfolio. The real news, however, comes from Anthropic, the company behind the AI assistant Claude, which is investing in the project for the first time.

Why Anthropic's involvement matters

Anthropic's presence in this funding round is no coincidence. Leading large language model companies are increasingly seeking concrete applications for their technology in sectors with real societal impact, and healthcare represents one of the most promising testing grounds. AI-assisted drug discovery can dramatically cut the time and costs associated with traditional research, which typically spans years and involves hundreds of millions of dollars just for the preclinical stages.

Basecamp Research is betting on exactly this promise: using advanced algorithms to analyze complex biological structures and more quickly identify compounds with therapeutic potential for diseases that are difficult to treat through conventional methods.

A clearer pattern emerging in AI investment

The funding arrives at a time when tech investors are actively seeking startups that combine generative AI with traditional fields such as biotechnology, computational chemistry, or genomics. Nvidia, through its hardware infrastructure, and Anthropic, through its expertise in language models, form a partnership that could give Basecamp Research not just capital but also direct technological access to cutting-edge tools.

The $140 million round places the British startup among the European biotech companies with the strongest backing from major AI names, in a year when global competition for innovation in healthcare has intensified considerably.